FY2025 EPS Estimates for ChromaDex Lifted by HC Wainwright

ChromaDex Co. (NASDAQ:CDXC) – Equities research analysts at HC Wainwright raised their FY2025 earnings per share estimates for ChromaDex in a report issued on Monday, November 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.21 for the year, up from their previous estimate of $0.12. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for ChromaDex’s current full-year earnings is $0.01 per share.

Separately, Roth Mkm raised their target price on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday.

ChromaDex Stock Performance

Shares of CDXC opened at $6.99 on Wednesday. The company has a market capitalization of $530.77 million, a P/E ratio of 699.00 and a beta of 1.88. ChromaDex has a fifty-two week low of $1.32 and a fifty-two week high of $7.08. The business’s 50-day moving average is $3.70 and its two-hundred day moving average is $3.28.

ChromaDex (NASDAQ:CDXC) last announced its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period in the prior year, the company posted ($0.01) EPS.

Hedge Funds Weigh In On ChromaDex

Large investors have recently bought and sold shares of the stock. Miracle Mile Advisors LLC purchased a new position in ChromaDex during the second quarter worth about $27,000. The Manufacturers Life Insurance Company purchased a new stake in ChromaDex in the 2nd quarter valued at approximately $31,000. Merriman Wealth Management LLC purchased a new stake in ChromaDex during the 2nd quarter worth about $32,000. Lazard Asset Management LLC purchased a new stake in shares of ChromaDex during the first quarter worth about $43,000. Finally, SG Americas Securities LLC acquired a new position in ChromaDex in the 1st quarter valued at $54,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Insider Transactions at ChromaDex

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 9.64% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.